Abstract: Male breast cancer is a rare disease. There are limited data to inform optimal treatment and follow-up strategies in this population. Currently, most follow-up guidelines are drawn from the vast literature on female breast cancer, despite the fact that male breast cancer has unique biological characteristics. In this review, we discuss clinical characteristics of male breast cancer as well as current best practices for long-term care with a focus on surveillance, screening, and treatment-related symptom management in male breast cancer survivors.


Keywords: male breast cancer, follow-up, surveillance, screening



Continue Reading

INTRODUCTION

Male breast cancer is a rare disease, comprising 1% of all breast cancer diagnoses and 0.25% of cancer diagnoses in men in the US.1,2 In 2015, it is estimated that 2,350 American men will be diagnosed with breast cancer and that 440 will die of the disease.3 Known risk factors for male breast cancer include genetic mutations (most notably, BRCA2), radiation exposure, increasing age, family history, and conditions that alter the estrogen/androgen balance, including Klinefelter syndrome.4–18However, little is known regarding optimal treatment and follow-up strategies for these patients. Currently, most male breast cancer care algorithms are extrapolated from the treatment and follow-up of female breast cancer patients, and data are particularly lacking regarding postcancer surveillance for male breast cancer survivors. In this manuscript, we review what is known about the clinical characteristics and treatment patterns seen in male breast cancer as a background for our discussion of best practices in surveillance, genetic testing, and management of side effects in male patients.

CLINICAL CHARACTERISTICS AND TREATMENTS

Cardoso et al recently reported the initial results of the EORTC10085/TBCRC/BIG/NABCG International Male Breast Cancer Program retrospective analysis, utilizing the largest collection of male breast cancer clinical characteristics and biological samples to date (N=1,483).19 This study confirmed previous research showing that male breast cancer has different biological characteristics than female breast cancer, with higher rates of hormone receptor positivity, older age at presentation, and higher proportion of nodal disease at presentation.2,20,21 In this large international cohort, only 10% of patients were 50 years or younger at diagnosis, the median age at diagnosis was 68 years, and 45% had node positive disease at presentation.